Shares of Biocept, Inc. (NASDAQ:BIOC) fell 8.8% during mid-day trading on Tuesday . The stock traded as low as $5.91 and last traded at $6.53. 611,336 shares were traded during trading, an increase of 2% from the average session volume of 600,041 shares. The stock had previously closed at $7.16.
Several research firms have recently issued reports on BIOC. Maxim Group began coverage on shares of Biocept in a research note on Friday, December 11th. They set a “buy” rating and a $20.00 target price on the stock. Zacks Investment Research lowered shares of Biocept from a “hold” rating to a “sell” rating in a research note on Monday, January 4th.
The firm’s 50 day moving average price is $6.26 and its 200-day moving average price is $5.50. The company has a debt-to-equity ratio of 0.06, a quick ratio of 2.52 and a current ratio of 2.85. The firm has a market capitalization of $87.48 million, a PE ratio of -1.62 and a beta of 0.86.
Biocept Company Profile (NASDAQ:BIOC)
Biocept, Inc, an early stage molecular oncology diagnostics company, develops and commercializes proprietary circulating tumor cell and circulating tumor DNA assays utilizing a standard blood sample. The company's cancer assays provide information to healthcare providers to identify oncogenic alterations that qualify a subset of cancer patients for targeted therapy at diagnosis, progression, and monitoring in order to identify resistance mechanisms.
Featured Story: Stock Symbols Definition, Examples, Lookup
Receive News & Ratings for Biocept Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biocept and related companies with MarketBeat.com's FREE daily email newsletter.